Please select an option below to help us tailor your newsletter to best suit your content interests!
A Phase 1/2a, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of PEN-866 in Patients With Advanced Solid Malignancies
VIEW TRIAL ON CLINICALTRIALS.GOVAnal cancer, Pancreatic cancer, PDAC, Cervix, cervical cancer, Gastric cancer, Gastroesophageal cancer, SCLC, Small cell lung cancer, penile, vulvar
Stage 4
Phase 1
Open to Enrollment
2nd or later
PEN-866
HSP-90 inhibitor
Dan Vaena, MD
Tarveda Therapeutics
adenocarcinoma or squamous cell carcinoma